
Keystone restrictions, market uncertainty weigh on South Bow earnings forecast
A segment of the Alberta-to-Texas system ruptured and spilled crude onto North Dakota farmland last month.
The Calgary-based company says earnings before interest, taxes, depreciation and amortization are expected to be around US$1.01 billion this year, as earlier predicted.
However, its most optimistic scenario would see one per cent added to that figure instead of three per cent.
But South Bow also said its more pessimistic scenario has improved thanks to better clarity over the impact of U.S. tariffs and strong first-quarter results.
It's now predicting a two-per-cent downside to its EBITDA, down from three per cent.
South Bow says about 90 per cent of its business is contracted, meaning it has very little risk.
It said it has been able to meet contractual commitments to ship 585,000 barrels of oil per day on Keystone. The system starts in Hardisty, Alta., and delivers oilsands crude to refineries in the U.S. Midwest and Gulf Coast, as well as the Cushing, Okla., storage hub.
During the first quarter, about 613,000 barrels per day flowed on the line, down from 643,000 a year earlier.
'We expect to deliver on our committed contracts for the remainder of the year, though we expect to have limited capacity to transport any uncommitted or spot volumes on our Keystone system with the pressure restrictions in place,' chief financial officer Van Dafoe told analysts on a conference call Friday.
In early April, a segment of South Bow's Keystone pipeline in North Dakota ruptured, spilling more than 556,000 litres of oil onto a field. It was able to bring the pipe back into service a week later, but regulators have ordered it to pump oil at a lower pressure for now.
Chief operating officer Richard Prior said 85 per cent of the spilled oil has been injected back into the pipeline, with the rest disposed of at an approved treatment facility.
The company aims to fully clean up the site by mid-year and expects insurance policies to cover the remediation costs.
Chief executive Bevin Wirzba said there are also contract provisions with customers that allow the company to collect tolls when a pipeline is out of commission.
'No incident is ever acceptable at South Bow, but I'm proud of the way our team came together and demonstrated South Bow's ability to execute and get our system back up quickly and effectively while meeting the expectations of our regulators, the surrounding community, and local leaders,' he said on the call.
'And the collaboration I witnessed throughout our organization showed our strength to be agile and perform as a stand-alone entity while coming together to find answers.'
South Bow was spun off from pipeline giant TC Energy last October.
Late Thursday, it said net income for the first three months of 2025 was US$88 million, down from US$112 million a year earlier, before it became an independent firm.
Net income per share was 42 cents US compared to 54 cents US during the first quarter of 2024.
Revenues were US$498 million, a drop from US$544 million a year earlier.
South Bow said there's more crude oil pipeline capacity in Western Canada than there is supply to fill it.
'As a result, the demand for uncommitted capacity on South Bow's Keystone Pipeline is expected to remain low in the near term,' it said.
'Additionally, rapidly changing global trade policies, including tariffs, have introduced economic and geopolitical uncertainty, leading to significant volatility in commodity prices and pricing differentials.'
This report by The Canadian Press was first published May 16, 2025.
Companies in this story: (TSX: SOBO) (TSX: TRP)
Note to readers:This is a corrected story. An earlier version had an incorrect figure for South Bow's earnings per share in the first quarter of 2024.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Hypebeast
32 minutes ago
- Hypebeast
From Seoul to the World: Anti Social Social Club Launches 'Designed in Korea' Line
Summary Following the milestone opening of its first global flagship store in South Korea earlier this year,Anti Social Social Club(ASSC) has launched its 'Designed in Korea' capsule collection. The line fuses the brand's early‑era identity with the contemporary creative energy of Seoul, resulting in a curated range of premium apparel and accessories. Each capsule will release in limited quantities, underscoring the label's reputation for exclusivity and collectability. The debut drop features heavyweight tees, fleece, jackets, hats, and accessories, all crafted from elevated materials with meticulous attention to detail. ASSC's Seoul‑based design team revisited the brand's archives to reinterpret signature graphics and silhouettes through a modern Korean lens, creating pieces that balance nostalgia with fresh, street‑ready appeal. Offered in sizes M through 2XL, the range is designed to cater to a broad audience while retaining ASSC's distinctive edge. With prices ranging from $42 – $121 USD, the 'Designed in Korea' line positions itself as an accessible yet premium addition to the streetwear market. Drop 1 is available now exclusively through Anti Social Social Club's officialwebsite.
Yahoo
2 hours ago
- Yahoo
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa
Immutep Limited (NASDAQ:IMMP) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, the company shared that it had received positive feedback from the U.S. FDA on the future clinical development of eftilagimod alfa (efti) for first-line treatment of head and neck squamous cell carcinoma patients with CPS <1. A line of biopharmaceutical products on a laboratory shelf waiting to be tested. The feedback stems from encouraging data from the TACTI-003 Phase 2b trial evaluating efti with MSD's anti-PD-1 KEYTRUDA (pembrolizumab). Immutep Limited (NASDAQ:IMMP) said that the FDA acknowledged the potential of the combination to address the high unmet need in patients with CPS <1 and supports its further development. Marc Voigt, CEO of Immutep Limited (NASDAQ:IMMP), shared the following remarks on the development: 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population.' Looking ahead, Immutep Limited (NASDAQ:IMMP) also outlined paths for future clinical development. This would include a randomised registrational trial evaluating the combination against standard-of-care therapy, or lead a smaller single-arm study on about 70-90 patients, followed by a confirmatory randomised study building on the existing findings. While we acknowledge the potential of IMMP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None.
Yahoo
2 hours ago
- Yahoo
Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating
Mesoblast Limited (NASDAQ:MESO) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, Canaccord Genuity initiated coverage of the stock with a Buy rating and announced a price target of AUD 2.97 ($1.94) per share, with analyst Elyse Shapiro citing the company's promising cell therapy platform. A close up of the hand of a financial analyst, holding a copy of a report from a rating agency. The firm acknowledged Mesoblast Limited (NASDAQ:MESO)'s expertise in allogeneic therapies for severe inflammatory diseases, which use cells from a single donor, instead of requiring cells from the recipient or matched donors. Canaccord also highlighted the company's progenitor cell and mesenchymal stromal cell approach that reduces harmful inflammation by modulating the immune system. In other recent news, on July 17, Mesoblast Limited (NASDAQ:MESO) announced USD 13.2 million in gross revenue from Ryoncil sales post-launch. The drug is the first and only mesenchymal stromal cell product in the U.S. that is approved by the FDA. It became commercially available on March 28, 2025, for the treatment of steroid-refractory acute graft-versus-host disease in children. Mesoblast Limited (NASDAQ:MESO) is an Australian company focused on developing allogeneic cellular medicines to treat severe and life-threatening inflammatory conditions. While we acknowledge the potential of MESO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio